References
1. Driessen EMC, De Lorenzo P, Campbell M, et al. Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol. Leukemia 2016;30:1184-1187.
2. Bhojwani D, Sposto R, Shah NN, et al. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Leukemia 2019;33:884-892.
3. Brivio E, Chantrain CF, Gruber TA, et al. Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukemia: A case series. Br J Haematol 2021;193:1172-1177.
4. Pieters R, De Lorenzo P, Ancliffe P, et al. Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the interfant-06 protocol: Results from an international phase III randomized study. J Clin Oncol 2019;37:2246-2256.
5. Jabbour EJ, Deangelo DJ, Stelljes M, Stock W, Liedtke M. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer 2018;124:1722-1732.
6. Stock W, Gökbuget N, Brien SO, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 2016;375:740-753.
7. McNeer JL, Rau RE, Gupta S, Maude SL, O’Brien MM. Cutting to the front of the line: Immunotherapy for childhood acute lymphoblastic leukemia. Am Soc Clin Oncol Educ B 2020;40:e132-e143.